miR-181d-5p ameliorates hypercholesterolemia by targeting PCSK9
Journal of Endocrinology · 2024
DOI: 10.1530/joe-23-0402 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Endocrinology, 2024. Verfasst von Yu Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing, China. Hauptthemen laut MEDLINE: Proprotein Convertase 9, MicroRNAs, Hypercholesterolemia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hypercholesterolemia is an independent risk factor for cardiovascular disease and lowering circulating levels of low-density lipoprotein cholesterol (LDL-C) can prevent and reduce cardiovascular events. MicroRNA-181d (miR-181d) can reduce the levels of triglycerides and cholesterol esters in cells. However, it is not known whether miR-181d-5p can lower levels of circulating LDL-C. Here, we generated two animal models of hypercholesterolemia to analyze the potential relationship between miR-181d-5p and LDL-C. In hypercholesterolemia model mice, adeno-associated virus (AAV)-mediated liver-directed overexpression of miR-181d-5p decreased the serum levels of cholesterol and LDL-C and the levels of cholesterol and triglyceride in the liver compared with control mice. Target Scan 8.0 indicated Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) to be a possible target gene of miR-181d-5p, which was confirmed by in vitro experiments. miR-181d-5p could directly interact with both the PCSK9 3′-UTR and promoter to inhibit PCSK9 translation and transcription. Furthermore, Dil-LDL uptake assays in PCSK9 knockdown Huh7 cells demonstrated that miR-181d-5p promotion of LDL-C absorption was dependent on PCSK9. Collectively, our findings show that miR-181d-5p targets the PCSK9 3′-UTR to inhibit PCSK9 expression and to reduce serum LDL-C. miR-181d-5p is therefore a new therapeutic target for the development of anti-hypercholesterolemia drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing, China.
- The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
- National Clinical Research Center for Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Fan Li
Zitieren
APA
Wang, Y., Li, F., Gao, X., Yu, H., Du, Z., Li, L., Du, Y., Hu, C., & Qin, Y. (2024). miR-181d-5p ameliorates hypercholesterolemia by targeting PCSK9. Journal of Endocrinology. https://doi.org/10.1530/joe-23-0402
Vancouver
Wang Y, Li F, Gao X, Yu H, Du Z, Li L, et al. miR-181d-5p ameliorates hypercholesterolemia by targeting PCSK9. Journal of Endocrinology. 2024. doi:10.1530/joe-23-0402
BibTeX
@article{Wang2024,
author = {Wang, Yu and Li, Fan and Gao, Xiaoqian and Yu, Huahui and Du, Zhiyong and Li, Linyi and Du, Yunhui and Hu, Chaowei and Qin, Yanwen},
title = {miR-181d-5p ameliorates hypercholesterolemia by targeting PCSK9},
journal = {Journal of Endocrinology},
year = {2024},
doi = {10.1530/joe-23-0402}
}
EUVIMED